Tags ophthalmology ophthalmology Eye diseases and vision: drugs for retinal disease, lenses and eye-care devices.
Theme · 5 companies · 0 report it as a revenue line
Sells it“AbbVie’s eye care products address unmet needs and new approaches to help preserve and protect patients’ vision.”
Latest 10-K FY2025 Positive Impairment / charge · Filed Feb 20
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue $61.2B YoY +8.6% Net income $4.2B YoY −1.2% Latest 10-Q Q3 FY2026 Positive · Filed Nov 3
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue $17.4B YoY +10.3% Net income $4.2B vs $186.0M year ago Latest 8-K Leadership change · Filed Nov 2
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Latest 8-K Positive Earnings Guidance raised Impairment / charge · Filed Oct 30
Skyrizi and Rinvoq growth offsets Humira declines; FY2026 adjusted EPS guidance raised to $13.95–$13.99
Latest 8-K Guidance reaffirmed Impairment / charge Deal completed · Filed Sep 3
Closed ≈$10.9B Apogee acquisition, adding late-stage zumilokibart for atopic dermatitis and an asthma combination candidate
Latest 8-K Debt financing · Filed Aug 18
Debt offering completed to help fund the Apogee Therapeutics acquisition and related costs.
Latest 8-K Deal pending · Filed Jun 22
Proposed Apogee acquisition adds clinical-stage atopic dermatitis and asthma programs, with near-term adjusted EPS dilution.
Latest 8-K Shareholder vote · Filed May 12
Bid to eliminate supermajority voting failed despite 98.9% support among votes cast for or against.
In development“In November 2025, we initiated a Phase 2 randomized, masked, placebo-controlled clinical trial of SC administered agazisiran in participants with GA secondary to AMD.”
Latest 424B4 final IPO prospectus Positive Pre-revenue · Filed Sep 25
Develops siRNA drugs for hereditary angioedema and other diseases; $446M all-primary raise funds clinical development
In development“CITY-RBP4 is a City-engineered GalNAc-conjugated siRNA therapeutic candidate designed to target RBP4 mRNA for the treatment of retinal diseases characterized by the toxic accumulation of vitamin A byproducts.”
Latest 424B4 final IPO prospectus Customer concentration · Filed Oct 16
Develops RNA interference drugs led by CITY-FXI for thrombosis; raises $200M entirely through new shares.
Sells it“The Vision portfolio includes contact lenses marketed under the ACUVUE brand, TECNIS premium intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures.”
Latest 10-K FY2025 · Filed Feb 11
DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.
Revenue $94.2B YoY +6.0% Net income $26.8B YoY +90.6% Latest 10-Q Q3 FY2026 Mixed Restructuring Impairment / charge Legal / investigation · Filed Oct 21
TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.
Revenue $25.4B YoY +5.9% Net income $210.0M YoY −95.9% Latest 8-K Earnings Guidance raised Impairment / charge Legal / investigation · Filed Oct 13
Talc litigation drives a $5.52B pre-tax adjustment; strong operations lift FY2026 adjusted EPS guidance to $11.05-$11.15
Latest 8-K Leadership change · Filed Aug 4
Tom Cavanaugh to succeed retiring Jennifer Taubert as Innovative Medicine chairman and join the Executive Committee Sept. 1, 2026.
Latest 8-K Negative Guidance lowered Impairment / charge Deal completed · Filed Jul 29
Firefly acquisition and Sail collaboration prompt cuts to 2026 adjusted EPS and operating-margin outlook.
Latest 8-K Positive Earnings Guidance raised Restructuring Impairment / charge · Filed Jul 15
Oncology and TREMFYA drive Innovative Medicine growth despite STELARA pressure; sales and adjusted EPS outlooks rise.
Latest 8-K Shareholder vote · Filed Apr 27
Shareholders rejected an independent board chair mandate and elected all director nominees.
Sells it“EYLEA HD received U.S. approval for dosing intervals up to 20 weeks in wet AMD and diabetic macular edema.”
Latest 10-Q Q3 FY2026 Positive · Filed Oct 30
Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.
Revenue $5.1B YoY +36.3% Net income $1.9B YoY +33.5% Latest 8-K Positive Earnings Guidance raised · Filed Oct 30
Higher Dupixent profit share and the end of Sanofi Development Balance deductions accelerated revenue growth to 36% Y/Y.
Latest 8-K Positive Earnings Impairment / charge Legal / investigation · Filed Oct 6
Expanded Sanofi pact covers four long-acting antibodies with $1.0B upfront and up to $7.0B in milestones, and settles information-access lawsuit.
Latest 8-K Executive pay · Filed Sep 30
10-year CEO and chief scientific officer equity awards replace annual grants through 2036, tying payouts to new-product revenue and pipeline milestones.
No companies have a recent 8-K matching these events. Show all 8-K events
No companies in the selected roles.